<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41947">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02014324</url>
  </required_header>
  <id_info>
    <org_study_id>NL42787.018.13</org_study_id>
    <nct_id>NCT02014324</nct_id>
  </id_info>
  <brief_title>Single Scope Staging of Lung Cancer With Endosonography</brief_title>
  <acronym>SCORE</acronym>
  <official_title>Complete Endosonographic Staging of Lung Cancer: a Systematic Single Scope Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Lung cancer is the most commonly diagnosed cancer worldwide and is the most
      frequent cause of cancer death. Accurate staging is important because it directs treatment
      and prognosis. Mediastinal staging can be done by both EBUS-TBNA and EUS-FNA. These two
      techniques have a complementary diagnostic range and the combined procedure is suited for
      assessment of almost the entire mediastinum. In practice, when mediastinal tissue staging is
      indicated, endoscopists often perform either an EBUS or an EUS investigation (instead of the
      combined procedure).  Second, frequently only one or two, by imaging suspected lymph node
      stations, are sampled (ie. targeted approach).

      Objectives: main and secondary:

        1. Complete endosonographic (combined endobronchial and esophageal) staging using a single
           EBUS scope improves locoregional staging (N2, N3, T4) versus EBUS staging alone.

        2. Systematic mediastinal staging results in improved locoregional staging compared to
           PET-CT directed assessment of the mediastinum (ie targeted approach).

      Study population: Patients with potentially operable and resectable NSCLC are eligible if
      there is an indication for mediastinal nodal sampling. Patients have an indication for
      EBUS-TBNA.

      Intervention: Patients will undergo an EBUS investigation followed by EUS-B in the same
      session. During this single scope procedure, lymph nodes that are suspected on prior CT-PET
      imaging and on subsequent ultrasound are sampled.

      Main study endpoint: The main study parameter is the sensitivity for locoregional disease
      (N2, N3, T4 disease) of complete endosonographic staging (by EBUS-TBNA and EUS-B-FNA) in
      comparison with EBUS staging alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>4 Weeks</target_duration>
  <primary_outcome>
    <measure>Sensitivity for locoregional disease (N2, N3, T4 disease).</measure>
    <time_frame>from inclusion untill either pathological proof of mediastinal metastases by endospnography or 1 week after surgical verification</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sensitivity is defined as number of true positives (pathologic proof of a nodal metastases) divided by the number of true positives and false negatives (thoracotomy with nodal dissection is the reference standard to detect false negatives).
The main study parameter is the sensitivity for locoregional disease (N2, N3, T4 disease) of complete endosonographic staging (by EBUS-TBNA and EUS-B-FNA) in comparison with EBUS staging alone.
In the event of pathological proof of mediastinal metastases (N2/N3) by endosonography patients are classified as having locally advanced disease (stage III) and the study stops. When no mediastinal metastases are found by endosonography, surgical verification will take place (reference standard).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity for locally advanced disease (N2-3 metastases, T4). Systematic assessment and sampling of mediastinal lymph nodes versus PET-CT directed assessment of the mediastinum.</measure>
    <time_frame>from inclusion untill either pathological proof of mediastinal metastases by endosonography or 1 week after surgical verification</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sensitivity for locally advanced disease (N2-3 metastases, T4) of systematic assessment and sampling of mediastinal lymph nodes in comparison to PET-CT directed assessment of the mediastinum (ie targeted approach).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">215</enrollment>
  <condition>Non Small Cell Lung Cancer (NSCLC)</condition>
  <condition>Indication Mediastinal Staging</condition>
  <condition>Complete Endosonography</condition>
  <arm_group>
    <arm_group_label>(suspected) NSCLC, mediastinal staging, endosonography</arm_group_label>
    <description>Patients with potentially medically operable and resectable NSCLC are eligible if there is an indication for pathological evaluation of mediastinal lymph nodes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endosonography</intervention_name>
    <description>Complete endosonographic mediastinal staging is performed in 2 steps:
Systematic EBUS (airways)
Systematic EUS-B (esophagus)</description>
    <arm_group_label>(suspected) NSCLC, mediastinal staging, endosonography</arm_group_label>
    <other_name>EBUS</other_name>
    <other_name>EUS-B</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with potentially operable and resectable NSCLC are eligible if there is an
        indication for mediastinal nodal sampling. Patients have an indication for EBUS-TBNA.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (Suspected) NSCLC;

          -  Indication for mediastinal nodal assessment;

          -  Suspected mediastinal lymph nodes within reach of EBUS;

          -  Age 18 years or older;

          -  Clinically fit to undergo surgical resection of the lung tumor;

          -  Provision of a written informed consent;

        Exclusion Criteria:

          -  Mediastinal re-staging after neo-adjuvant treatment;

          -  Indication for EUS other than mediastinal staging, eg a for malignancy

          -  suspected left adrenal;

          -  Active malignancy with a life expectancy of less than two years;

          -  Former therapy for lung cancer (chemotherapy, radiotherapy or surgery);

          -  Technical contraindication for  EBUS or EUS (eg, esophagus stenosis);

          -  Pregnancy;

          -  Inability to consent;
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jouke T Annema, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze-Lieve-Vrouwen-Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>K Tournoy, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>K Tournoy, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>C Dooms, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>C Dooms, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>P Clementsen, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>P Clementsen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence MMJ Crombag, MD</last_name>
      <phone>+31205664356</phone>
      <email>l.m.crombag@amc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Jouke T Annema, Prof Dr</last_name>
      <phone>+3120564356</phone>
      <email>j.t.annema@amc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Laurence MMJ Crombag, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Welling, MD</last_name>
      <phone>+31-72 - 548 27 50</phone>
      <email>a.welling@mca.nl</email>
    </contact>
    <investigator>
      <last_name>A Welling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JMA Daniels, MD</last_name>
    </contact>
    <investigator>
      <last_name>JMA Daniels, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>WA Buikhuisen, MD PhD</last_name>
      <phone>+31-20 - 512 29 58</phone>
      <email>w.buikhuisen@nki.nl</email>
    </contact>
    <investigator>
      <last_name>WA Buikhuisen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SRS Ramai, MD</last_name>
      <phone>+31-71 - 526 29 50</phone>
      <email>S.R.S.Ramai@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>SRS Ramai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum st Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HFM van der Heijden, MD</last_name>
      <phone>024 - 361 45 79</phone>
      <email>h.vanderheijden@longumcn.nl</email>
    </contact>
    <investigator>
      <last_name>HFM van der Heijden, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JA Stigt, MD</last_name>
      <phone>+31-38 - 424 24 56</phone>
      <email>j.a.stigt@isala.nl</email>
    </contact>
    <investigator>
      <last_name>JA Stigt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 12, 2013</lastchanged_date>
  <firstreceived_date>May 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Prof J.T. Annema</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
